177 related articles for article (PubMed ID: 25316507)
1. Myeloid neoplasm with translocation t(2;11)(p21;q23-24), elevated microRNA 125b-1, and JAK2 exon 12 mutation.
McCormick SR; Higgins RR; Grutkoski PS; Bousquet M; Quelen C; Bartholomaus LM; Brousset P
Br J Haematol; 2015 Apr; 169(2):290-3. PubMed ID: 25316507
[No Abstract] [Full Text] [Related]
2. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates.
Patnaik MM; Knudson RA; Gangat N; Hanson CA; Pardanani A; Tefferi A; Ketterling RP
Eur J Haematol; 2010 Jun; 84(6):518-24. PubMed ID: 20331734
[TBL] [Abstract][Full Text] [Related]
3. Myelodysplastic syndrome with a t(2;11)(p21;q23-24) and translocation breakpoint close to miR-125b-1.
Thorsen J; Aamot HV; Roberto R; Tjønnfjord GE; Micci F; Heim S
Cancer Genet; 2012 Oct; 205(10):528-32. PubMed ID: 22944560
[TBL] [Abstract][Full Text] [Related]
4. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Hussein K; Bock O; Kreipe H
Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
[TBL] [Abstract][Full Text] [Related]
5. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
6. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.
Siemiatkowska A; Bieniaszewska M; Hellmann A; Limon J
Leuk Res; 2010 Mar; 34(3):387-9. PubMed ID: 19643476
[TBL] [Abstract][Full Text] [Related]
7. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
Smith CA; Fan G
Hum Pathol; 2008 Jun; 39(6):795-810. PubMed ID: 18538168
[TBL] [Abstract][Full Text] [Related]
8. Apparent 'JAK2-negative' polycythaemia vera due to compound mutations in exon 14.
Tiong IS; Casolari DA; Moore S; Nguyen T; Van Velzen MJM; Zantomio D; Scott HS; D'Andrea RJ; Hahn CN; Ross DM
Br J Haematol; 2017 Jul; 178(2):333-336. PubMed ID: 27136492
[No Abstract] [Full Text] [Related]
9. A myeloproliferative neoplasm with translocation t(8;9)(p22;p24) involving JAK2 gene.
Saba N; Safah H
Blood; 2013 Aug; 122(6):861. PubMed ID: 24079014
[No Abstract] [Full Text] [Related]
10. Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations.
Lakey MA; Pardanani A; Hoyer JD; Nguyen PL; Lasho TL; Tefferi A; Hanson CA
Am J Clin Pathol; 2010 Jun; 133(6):942-8. PubMed ID: 20472853
[TBL] [Abstract][Full Text] [Related]
11. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
12. A t(8;9)(p22;p24)/PCM1-JAK2 translocation in a patient with myeloproliferative neoplasm and myeloid sarcoma: first report in Korea.
Song I; Lee DH; Lee JH; Jang S; Huh JR; Seo EJ
Ann Lab Med; 2016 Jan; 36(1):79-81. PubMed ID: 26522767
[No Abstract] [Full Text] [Related]
13. MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
Ma W; Zhang X; Wang X; Zhang Z; Yeh CH; Uyeji J; Albitar M
Diagn Mol Pathol; 2011 Mar; 20(1):34-9. PubMed ID: 21326037
[TBL] [Abstract][Full Text] [Related]
14. JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases.
Schnittger S; Bacher U; Kern W; Haferlach T; Haferlach C
Leukemia; 2007 Aug; 21(8):1843-5. PubMed ID: 17443220
[No Abstract] [Full Text] [Related]
15. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow.
Ingram W; Lea NC; Cervera J; Germing U; Fenaux P; Cassinat B; Kiladjian JJ; Varkonyi J; Antunovic P; Westwood NB; Arno MJ; Mohamedali A; Gaken J; Kontou T; Czepulkowski BH; Twine NA; Tamaska J; Csomer J; Benedek S; Gattermann N; Zipperer E; Giagounidis A; Garcia-Casado Z; Sanz G; Mufti GJ
Leukemia; 2006 Jul; 20(7):1319-21. PubMed ID: 16617322
[No Abstract] [Full Text] [Related]
16. [JAK2 mutation and thrombosis - recommendations for screening].
Linnemann B; Lindhoff-Last E
Dtsch Med Wochenschr; 2011 Dec; 136(48):2454-7. PubMed ID: 22109574
[No Abstract] [Full Text] [Related]
17. [Not Available].
Bächli E; Gundelfinger M
Praxis (Bern 1994); 2017 Jul; 106(15):807-813. PubMed ID: 28745110
[No Abstract] [Full Text] [Related]
18. Two alternatively spliced 5'BCR/3'JAK2 fusion transcripts in a myeloproliferative neoplasm with a three-way t(9;18;22)(p23;p11.3;q11.2) translocation.
Impera L; Lonoce A; Fanfulla DA; Moreilhon C; Legros L; Raynaud S; Storlazzi CT
Cancer Genet; 2011 Sep; 204(9):512-5. PubMed ID: 22018274
[TBL] [Abstract][Full Text] [Related]
19. Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis.
Cappetta M; Pérez V; Zubillaga MN; Elizondo V; Manrique G; Prosper I; Boschi S; Bonomi R; Pomoli S; Díaz L; Martínez L; Uriarte MR
Int J Lab Hematol; 2013 Feb; 35(1):e4-5. PubMed ID: 23062104
[No Abstract] [Full Text] [Related]
20. [Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection].
Andrikovics H; Szilvási A; Meggyesi N; Király V; Halm G; Lueff S; Nahajevszky S; Mikala G; Sipos A; Lovas N; Csukly Z; Mátrai Z; Tamáska J; Tordai A; Masszi T
Orv Hetil; 2007 Feb; 148(5):203-10. PubMed ID: 17344140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
